Navigation Links
bcr/abl, t(9;22) Translocation Quantitative Assay by RT-PCR

Productsbcr/abl, t(9;22) Translocation Quantitative Assay by RT-PCR
Company ARUP Laboratories
Item bcr/abl, t(9;22) Translocation Quantitative Assay by RT-PCR
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. bcr/abl, t(9;22) Translocation Qualitativeby RT-PCR
2. AML1-ETO, t(8;21) Translocation by RT-PCR
3. API2-MLT1,t(11;18) Translocation by RT-PCR
4. bcl-1/JH, t(11;14) Translocation by PCR, Fluid
5. bcl-1/JH, t(11;14) Translocation by PCR, Paraffin
6. bcl-2/JH mbr Quantification, t(14;18) Translocation by PCR, Paraffin
7. bcl-1/JH, t(11;14) Translocation by PCR, Tissue
8. bcl-2/JH mbr Quantification, t(14;18) Translocation by PCR, Tissue
9. bcl-2/JH, t(14;18) Translocation by PCR, Paraffin
10. bcl-2/JH, t(14;18) Translocation by PCR, Tissue
11. bcl-2/JH mbr Quantification, t(14;18) Translocation by PCR, Fluid
...m DePuy offers a comprehensive combination of comf...commendations regarding occupational exposure to b...d for comfort. , ,The Nighthawk, a new additio...personal protection system for the healthcare prof...
Ideal for sensory nerve testing, Cadwells finger clip electrodes are constructed of solid, surgical-grade stainless steel and come with color-coded handles and ultra-flexible, red-and-black twisted p
Cadwells stainless steel ring electrodes feature a molded grip for convenient handling and an adjustable slider that moves smoothly and locks firmly in one motion. Cadwell rings also feature ultrafle
Silver/silver chloride ground has a large surface area for superb patient grounding. For use with minicrocodile clip lead wires. Dimensions: 4.5 cm (1.75 in) long, 3.1 cm (1.25 in) wide. Each 100-cou
Medicine Products:
(Date:11/21/2008)...fresh from basic training and now serving overseas...fe he saved by donating his rare blood type. , ... Korea (PRWEB) November 21, 2008 -- A local Korean...on saved her life, met for the first time when she...Airman Tamarias Pope, 8th Security Forces Squadron...
(Date:11/21/2008)...eld on January 8, 2009 , , TORONTO, Nov. 21...Inc. ("MedEmerg") (OTCBB: MDER), one of Canada,s l...ay that it has obtained an interim order from the ...reviously announced plan of arrangement (the "Arra...("AIM") will acquire all of MedEmerg,s outstanding...
(Date:11/21/2008)...rstCall/ -- Heska Corporation,(Nasdaq: HSKA ) t...iety of,Security Analysts, 12th Annual Biotech an... at 1177 Avenue of the Americas, 2nd Floor in New ...at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain Tim...two weeks,following the presentation through a li...
(Date:11/21/2008)...gainst Lennox-Gastaut syndrome , , FRIDA...anzel (rufinamide) has been approved as a suppleme...ed Lennox-Gastaut syndrome, the U.S. Food and Drug...l was based on results of a four-month clinical tr...to patients who took a placebo, those who took the...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
... 23rd man had succumbed to the deadly H5N1 bird fl...an has tested// positive to the same virus. The H5...e over Europe and Africa and has flared up once ag...lth Organization, some 105 people have fallen a vi...
...eople on vegetarian diets have highly effective we...er// than meat-eaters, and they experience lower r...re, and other life-threatening conditions linked t...lied from 87 previous studies and it shows the wei...
...ite making in-depth analysis in the field of atten...ychiatric problem that affects the children. As ...cation, which is beyond the scientists' control, b...gsters diagnosed with ADHD suffer co-existing cond...
... in cancer patients, as a new method of delivering...thout causing any side effects such as hair loss a... at the University of Bath, England, involves usin...emotherapy drug, which are then implanted into the...
Other Medicine News:Health News:Despite More Studies Researchers Are Still Confound With ADHD 2Health News:New Method Developed To Cut Down Chemotherapy Deaths 2
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
(Date:11/19/2008)...m Roche- , , MONTVALE, N.J., Nov. 19 /PRNew...Nasdaq: MEMY ) today announced that it has achie...3487/MEM 3454, its lead alpha-7 nicotinic receptor...schizophrenia (CIAS). The Company has randomized ....0 million payment from its partner Roche. Memory...
(Date:11/18/2008)...ire-USNewswire/ -- Forty-two leading U. S. scienti...l forum to consider cutting-edge innovations that ...onomy from outbreaks of dangerous zoonotic disease...ng those innovations: , , , , A...at detects highly contagious and dangerous zoonoti...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Nature study demonstrates that bacterial clotting depends on clustering 5691 1Nature study demonstrates that bacterial clotting depends on clustering 5691 2Excess Weight Seems to Boost Breast Cancer Risk 28489 1Excess Weight Seems to Boost Breast Cancer Risk 28489 2Excess Weight Seems to Boost Breast Cancer Risk 28489 3Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 1Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 1Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 10
...h VELCADE, lenalidomide,and dexamethasone , ,KOS, ...um,Pharmaceuticals, Inc. (Nasdaq: MLNM) today repo...ical trials of VELCADE based,therapies that showed... / complete response(1) (CR) rates in newly diagno...e presented at the,prestigious 11th International ...
..., 2007 - The drug most,commonly used to arrest pre... another common treatment to cause mild to serious...udy from researchers at,Lucile Packard Children,s ...e. Their findings suggest that, since the effectiv... should consider side,effects more strongly when c...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 2Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 3Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 4